SER - Serina Therapeutics Year-over-year earnings per share growth for the last twelve months

Serina - graphic logo of issuer SER

Serina Therapeutics, Inc. (SER) develops polymer delivery systems for drugs treating chronic brain pathologies. Quarterly earnings per share growth helps assess the issuer's real value, with 30.30 recorded as the baseline value. The POZ ecosystem provides long-term licensing for Parkinson's disease therapy, while the implementation of software robots in data analysis accelerates the time-to-market for new drugs.

Serina Therapeutics (SER) Year-over-year earnings per share growth for the last twelve months: for the period 03/28/2024 - 11/18/2026

Metric breakdowns and analytics for Serina Therapeutics (SER)

- market value and analyst target forecast:
- market capitalization statistics:
Comprehensive company analysis:Serina Therapeutics, Inc.
Flagship merchandise of serinatherapeutics.com

The stability of Serina Therapeutics, Inc. (SER) is determined by the effectiveness of its R&D pipeline and the control over the burn rate prior to reaching the commercialization stage. Analyzing the dynamics of net income per share allows for an assessment of management's ability to optimize costs; therefore, the current quarterly EPS growth rate serves as an indicator of operational resilience and warns investors of unforeseen losses in the event of development failures.

Competitors of Serina Therapeutics, Inc. (SER)

JAZZ (Jazz Pharmaceuticals PLC) - Year-over-year net earnings per share growth for the last 12 months|Cytokinetics Corp (CYTK) - Quarterly EPS earnings growth|Year-over-year earnings per share growth for the last twelve months PTC Therapeutics, Inc.|SRRK: Year-over-year earnings per one share growth for the last 12 months|Year-over-year earnings per share growth for the last twelve months Centessa Corp (CNTA)|Year-over-year earnings per share growth for the last twelve months DYN (Dyne Therapeutics Inc)|Year-over-year earnings per share growth for the last twelve months Edgewise Pharma EWTX|Rapport Corp - Year-over-year earnings per share growth for the last twelve months|ALMS - Year-over-year earnings per share growth for the last twelve months|Earnings per share growth in annualized terms for the last twelve months Zevra Therapeutics|CTNM: Quarterly EPS earnings growth|Net earnings per share growth for the trailing year Larimar Pharma LRMR|Year-over-year net earnings per share growth for the last 12 months CAPR|Earnings per share growth in annualized terms for the last twelve months Entrada TRDA|Quarterly EPS earnings growth PTHS|Year-over-year net earnings per share growth for the last 12 months MediciNova MNOV|Quarterly EPS earnings growth BTAI (BioXcel Therapeutics Inc)|ProMIS Neurosciences (PMN) - Earnings per share growth in annualized terms for the last twelve months|Apimeds Pharmaceuticals, Inc. - Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months AEON Biopharma, Inc.|NLSP (NLS Pharma) - Year-over-year net earnings per share growth for the last 12 months|Year-over-year earnings per share growth for the last 12 months BNOX|Year-over-year earnings per share growth for the last twelve months FSD Pharma|Quarterly EPS earnings growth Reata